Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency

AIMS: Early‐onset emphysema attributed to α‐1 antitrypsin deficiency (AATD) is frequently overlooked and undertreated. RAPID‐RCT/RAPID‐OLE, the largest clinical trials of purified human α‐1 proteinase inhibitor (A(1)‐PI; 60 mg kg(–1) week(–1)) therapy completed to date, demonstrated for the first ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Tortorici, Michael A., Rogers, James A., Vit, Oliver, Bexon, Martin, Sandhaus, Robert A., Burdon, Jonathan, Chorostowska‐Wynimko, Joanna, Thompson, Philip, Stocks, James, McElvaney, Noel G., Chapman, Kenneth R., Edelman, Jonathan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651313/
https://www.ncbi.nlm.nih.gov/pubmed/28662542
http://dx.doi.org/10.1111/bcp.13358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651313/
https://www.ncbi.nlm.nih.gov/pubmed/28662542
http://dx.doi.org/10.1111/bcp.13358

Ejemplares similares